RPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Royalty Pharma PLC (RPRX) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock shows strong fundamentals, positive analyst sentiment, and steady financial growth. While there are no immediate trading signals, the stock's long-term potential makes it a solid investment choice.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 64.95, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of 49.846, with a pivot at 48.951 and support at 48.055.
Hedge funds are significantly increasing their positions, with a 100.83% increase in buying activity last quarter.
Analysts have consistently raised price targets, with UBS, Morgan Stanley, and TD Cowen projecting targets between $50 and $
The company has a strong pipeline of biopharma catalysts and long-term growth potential.
The launch of the Translational Medicine Prize highlights the company's commitment to innovation.
Insiders are neutral, with no significant trading trends.
The stock's short-term trend indicates a potential decline of -0.66% in the next week and -1.37% in the next month.
In Q4 2025, Royalty Pharma reported a 4.78% YoY increase in revenue to $621.99M, a 2.88% YoY increase in net income to $214.21M, and a 6.38% YoY increase in EPS to $0.50. Gross margin remained strong at 100%.
Analysts are highly optimistic about RPRX, with multiple firms raising price targets and maintaining Buy or Overweight ratings. UBS projects $57, Morgan Stanley $63, and TD Cowen $50, citing the company's strong growth profile, biopharma catalysts, and diversified portfolio.
